MedTrace Logo

SIZOMUS Safety of Ixazomib Targeting Plasma Cells in Multiple Sclerosis

NCT03783416 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 72

Last updated 2025-09-04

No results posted yet for this study

Summary

The study seeks to investigate safety and efficacy of ixazomib (NINLARO), a proteasome inhibitor, in multiple sclerosis (MS). Participants will receive either ixazomib capsules or placebo capsules for up to 24 months.

Conditions

Interventions

DRUG

Ixazomib (NINLARO®) capsules / Matching placebo capsules

Participants will be treated for a maximum of 24 months

Sponsors & Collaborators

  • Takeda Pharmaceuticals International, Inc.

    collaborator INDUSTRY

  • Queen Mary University of London

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-06-15
Primary Completion
2026-07-31
Completion
2026-07-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03783416 on ClinicalTrials.gov